Hormonal contraceptive product

• US 20050004088A1
• Filed: 05/07/2004
• Published: 01/06/2005
• Est. Priority Date: 09/11/1997
• Status: Abandoned Application

• Current Assignee: Rolf-Dieter Hesch
• Original Assignee: Rolf-Dieter Hesch
• Inventors: Hesch, Rolf-Dieter
• Application Number:
  US10/841,278
• Publication Number:
  US 20050004088A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 5/24 of the sex hormones

Abstract

The present invention relates to a hormonal contraceptive product having two hormonal components, an estrogen and a gestagen, and a method for the continuous suppression of the menstrual cycle by uninterrupted administration of the product of the invention.

Claims

1. A method for hormonal contraception, comprising administering orally, transdernally or via depot to a mammal in need thereof, for a continuous and uninterrupted administration period, a contraceptive product comprising levonorgestrel and ethinyl estradiol, wherein said levonorgestrel and ethinyl estradiol are present in said contraceptive product at unchanged dosages throughout the administration period.

2. The method of claim 1, wherein said ethinyl estradiol is present at a dosage of 1-20 μ

g per day.

3. The method of claim 2, wherein the administration is oral.

4. The method of claim 3, wherein the administration period is 9 months.

5. The method of claim 3, wherein the administration period is 12 months.

6. A method for continuous suppression of the menstrual cycle in a woman, comprising administering orally, transdermally or via depot to the woman in need thereof, for a continuous and uninterrupted administration period, a contraceptive product comprising levonorgestrel and ethinyl estradiol, wherein said levonorgestrel and ethinyl estradiol are present in said contraceptive product at unchanged dosages throughout the administration period.

7. The method of claim 6, wherein said ethinyl estradiol is present at a dosage of 1-20 μ

g per day.

8. The method of claim 7, wherein the administration is oral.

9. The method of claim 8, wherein the administration period is 9 months.

10. The method of claim 8, wherein the administration period is 12 months.

11. A method for treating or inhibiting premenstrual syndrome, which comprises administering orally, transdermally, or via depot, to a mammal in need thereof, for a continuous and uninterupted administration period, an effective amount of a gestagen and an estrogen, wherein said gestagen and estrogen are present in unchanged dosages throughout the administration period.

12. The method of claim 11, wherein said gestagen is selected from the group consisting of progesterone, chlormadinone acetate, northisterone acetate, cyprotherone acetate, desogestrel, and levonorgestrel;

and

said estrogen is selected from the group consisting of ethinyl estradiol, mestranol, estradiol, estriol, estrone, and estrane.

13. The method of claim 12, wherein said estrogen is ethinyl estradiol, which is present at a dosage of 1-20 μ

g per day.

14. The method of claim 13, wherein said gestagen is levonorgesterel.

15. The method of claim 14, wherein the administration is oral.